SCHEMBL2964444

SCHEMBL2964444

Cc1ccc(Oc2ccc(O)cc2)c(Nc2ccnc3nc(C)ccc23)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 2/20 0.39
KDR P35968 2/20 0.39
MAPKAPK2 P49137 1/20 0.38
PIM1 P11309 1/20 0.37
AKT2 P31751 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ADORA1 P30542 1/20 0.35
HPGD P15428 1/20 0.34
IGF1R P08069 2/20 0.34
MAPT P10636 2/20 0.34
SYK P43405 1/20 0.34
AURKB Q96GD4 1/20 0.34
INCENP Q9NQS7 1/20 0.34
KCNH2 Q12809 1/20 0.34
GAA P10253 2/20 0.33
ATM Q13315 1/20 0.33
ENPP1 P22413 1/20 0.33
TGFBR1 P36897 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955700 0.89 IGF1R (0.45) RIPK2KDRMAPKAPK2PIM1AKT2
SCHEMBL2960952 0.89 ADORA1 (0.46) KDRMEN1KMT2AADORA1HPGD
SCHEMBL2971758 0.80 MAPKAPK2 (0.46) RIPK2MAPKAPK2MEN1KMT2AADORA1
SCHEMBL2969814 0.78 ADORA1 (0.45) RIPK2KDRMEN1KMT2AADORA1
SCHEMBL2015588 0.78 PIM1 (0.49) RIPK2KDRMAPKAPK2PIM1AKT2
SCHEMBL2968548 0.78 IGF1R (0.42) RIPK2MAPKAPK2KMT2AHPGDIGF1R
SCHEMBL2955707 0.76 IGF1R (0.41) RIPK2MAPKAPK2KMT2AIGF1RMAPT
SCHEMBL2970983 0.76 NR4A2 (0.42) KDRKMT2AHPGDIGF1RMAPT
SCHEMBL2968878 0.76 IGF1R (0.47) KDRMEN1KMT2AIGF1RMAPT
SCHEMBL2968819 0.76 IGF1R (0.45) KMT2AHPGDIGF1RMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 RIPK2 3496/4885KDR 3293/4885MAPKAPK2 3663/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 RIPK2 3496/4885KDR 3293/4885MAPKAPK2 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.